Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14670)	9/16/2000 11:35:50 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacaito, you criticize XOMA past trials and management but you seem to want, and keep mentiong $300 million, to run a new trial in less than optimal conditions. Why are you playing this game? You don't really seem to want them to succed but rather to bankrup them. There is no reason to run another meningococcemia trial. Castello has said they will use commercially practical methods to seek approval. and if these fail then so be it. In the meantime, unbeknowst to you since you don't pay attention to post, Baxter has chosen another indication. What it is I don't know. When it goes into clinic, exactly, I don't know. But, guess what I do know XOMA has said by 2001 and by year end. Works for me!!